Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.50, $0.02 better than the analyst estimate of $0.48. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.48 billion.

GUIDANCE:

Boston Scientific sees FY2023 EPS of $1.99-$2.02, versus the consensus of $2.00. The company now estimates net sales growth for the full year 2023, versus the prior year period, to be approximately 11 percent on both a reported basis and organic basis.

Boston Scientific sees Q4 2023 EPS of $0.49-$0.52, versus the consensus of $0.52. The company estimates net sales growth for the fourth quarter of 2023, versus the prior year period, to be in a range of approximately 9 to 11 percent on a reported basis, and approximately 8 to 10 percent on an organic basis.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.